Nordic Nanovector board members jump ship

 

Publisher’s Note: Due to overwhelming demand, nominations for the Fierce Biotech Innovation Awards have been extended to Thursday, September 22nd. Enter today.

Today's Big News

Sep 16, 2022
 

AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3

Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential 

With 70% staff gone, Nordic Nanovector board members jump ship amid 'strategic review'

With cash evaporating quickly, Palisade Bio cuts staff to save money and focus on sole GI med

Amgen CEO Robert Bradway warns Biden's Inflation Reduction Act could blunt future biotech success stories 

'The Top Line': What Merck trial flops at ESMO may portend, lessons from COVID for monkeypox test EUAs and more

Novartis headquarters raided in Swiss competition authority's patent probe  

NYU puts forward cancer test to help predict the success and toxicity of checkpoint inhibitor immunotherapies 

'Unsustainable' losses are forcing hospitals to make 'heart-wrenching' cuts and closures, leaders warn 

Chutes & Ladders—Biden lands on leader for new agency that will oversee 'cancer moonshot' initiatives

Fierce Pharma Asia—Takeda's €300M production boost; Daiichi, Dizal ESMO wins

IQVIA Thank you to IQVIA for sponsoring our editorial feature: Fierce Biotech's 2022 Fierce 15 
 

Featured

 

AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3

AstraZeneca’s $39 billion acquisition of Alexion last year continues to look like money well spent. The latest good news is that the oral factor D inhibitor danicopan can improve hemoglobin levels when added to the approved drugs Ultomiris or Soliris.
 
 
 
 

Top Stories

 

Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential

Intellia Therapeutics is closing out the week strong, reporting good news for a duo of gene editing trials. Both are early-stage, but the company is already prepping to move the transthyretin amyloidosis therapy, NTLA-2001, into what it hopes will be a pivotal study.
 
 
 

With 70% staff gone, Nordic Nanovector board members jump ship amid 'strategic review'

Nordic Nanovector is shedding board members as the Norwegian biotech continues to seek out options for survival in the wake of discontinuing its lymphoma trial.
 
 
 

Are You Prepared for Next-Gen Biomanufacturing?

The rapidly evolving field of genomic medicines has manufacturers scrambling to scale up the production of complex medicines. Flexible, automated and integrated technologies are the solution.

 
 
 

With cash evaporating quickly, Palisade Bio cuts staff to save money and focus on sole GI med

Just a month after raising nearly $14 million through a public offering, Palisade Bio is cutting 20% of staff to shore up dwindling funds. The company is directing all resources towards its sole GI-focused asset.
 
 
 

Amgen CEO Robert Bradway warns Biden's Inflation Reduction Act could blunt future biotech success stories

In an era of abundant pharma buyouts, small and midsized biotechs may find it increasingly difficult to go their own way, Amgen’s CEO Robert Bradway figures. And new drug cost legislation in the U.S. certainly won’t help, the helmsman added.
 
 
 

'The Top Line': What Merck trial flops at ESMO may portend, lessons from COVID for monkeypox test EUAs and more

This week on "The Top Line," we chat about this year’s European Society for Medical Oncology meeting, where Merck presented a series of trial flops for Keytruda. We also discuss the lessons learned from the COVID-19 pandemic and how they are being applied to the monkeypox test EUA.
 
 
 

Novartis headquarters raided in Swiss competition authority's patent probe

Some guests recently “visited” Novartis’ headquarters in Basel, the company said. But according to Switzerland’s anti-competition watchdog, it was a raid.
 
 
 

NYU puts forward cancer test to help predict the success and toxicity of checkpoint inhibitor immunotherapies

Researchers at NYU have developed a single test they say can help determine which patients may see their cancer return after treatment with immunotherapies, as well as who may be at risk for severe side effects.
 
 
 

'Unsustainable' losses are forcing hospitals to make 'heart-wrenching' cuts and closures, leaders warn

A new report warns that anywhere from 53% to 68% of the nation's hospitals will finish 2022 with red operating margins. For systems large and small, this means service line closures or outright shutdowns that threaten patients' access to care, hospital leaders warned Thursday.
 
 
 

Chutes & Ladders—Biden lands on leader for new agency that will oversee 'cancer moonshot' initiatives

President Joe Biden has landed on a leader for his new federal biotech agency aimed at overseeing his ambitious “cancer moonshot” initiatives.
 
 
 

Fierce Pharma Asia—Takeda's €300M production boost; Daiichi, Dizal ESMO wins

Takeda is investing heavily in plasma-derived therapy amid rapid growth. Daiichi Sankyo and AstraZeneca spinout Dizal Pharma are moving their respective lung cancer prospects ahead based on promising clinical data. President Joe Biden has launched a biomanufacturing initiative, which is widely viewed as a response to China's growing industry. And more.
 
 
 
 
Fierce podcasts

Don't miss an episode

 

'The Top Line': What Merck trial flops at ESMO may portend, lessons from COVID for monkeypox test EUAs and more

This week on "The Top Line," we chat about this year’s European Society for Medical Oncology meeting, where Merck presented a series of trial flops for Keytruda. We also discuss the lessons learned from the COVID-19 pandemic and how they are being applied to the monkeypox test EUA.
 
 

Resources

 
eBook

Make the most out of hybrid conferences

Improve your congress competitive intelligence and cut down costs by 50%

 
 
 
Whitepaper

Achieving faster formulation for First In Human supplies

Supporting your product development programme through experience, expertise, and efficiency.

 
 
 
eBook

Optimize Digital Engagement Across the Patient Journey

Improve patient engagement, adherence, and outcomes
 
 
 
Whitepaper

Unifying the Digital & Physical Building Hospital Resilience

Learn how IT and facility security professionals are collaborating on key initiatives to mitigate digital and physical security risks and build resilience healthcare system-wide.
 
 
 
Video

Building a Broader Tissue Research Ecosystem

Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue.
 
 
 
Video

Improve Life Sciences Research with AI Workflow Automation

Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster?
 
 
 
Whitepaper

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
 
 
 
Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.
 
 
 
Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
 
 
 
Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

 
 
 
Webinar

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.
 
 
 
Whitepaper

An Assay Platform to Evaluate Cytokine Release & T Cell Activation

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

 
 
 
Custom Resource Center

Scaling life sciences companies: Discover resources to support growth and innovation

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

 
 
 
Whitepaper

Expanding Healthcare Services with Digital Agreement Technology

Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

 
 
 
Research

Revealing better ways to do business with agile analytics

Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members

 
 
 
Executive Summary

Leading lab instruments provider saves $2M a year

How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers

 
 
 
Whitepaper

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

 
 
 
Whitepaper

Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

 
 
 
Whitepaper

Medical Affairs Metamorphosis, Part III: How Medical Affairs is Becoming a Key Hub for Evidence Generation

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

 
 
 
Whitepaper

Plan for scalable process liquid and buffer preparation

Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation.

 
 
 
Research

Reduce control arm sizes by up to 22% for HD & ALS RCTs

TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases.

 
 
 
eBook

Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

 
 
 
Whitepaper

Catalent Pulmonary & Nasal Delivery Capabilities Sheet

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

 
 
 
Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

 
 
 
Multimedia

Lead the way to the next breakthrough

ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation

 
 
 
 

Industry Events